Core Viewpoint - The company has received production registration approvals from the National Medical Products Administration of China for two pharmaceutical products, enhancing its portfolio in the ophthalmic and gastrointestinal preparation sectors [1] Group 1: Product Approvals - The company obtained a production registration for Levofloxacin Eye Drops (0.488% in 5ml, containing 24.4mg), classified as a Class 4 chemical drug, which is considered to have passed the consistency evaluation. This product is primarily used for treating various eye conditions such as blepharitis, conjunctivitis, and for sterile chemotherapy during ophthalmic surgeries [1] - The company also received approval for Compound Magnesium Sulfate Granules (10mg per bag), classified as a Class 3 chemical drug, which is also considered to have passed the consistency evaluation. This product is mainly used for bowel cleansing prior to colonoscopy and X-ray examinations, as well as for bowel preparation before surgical procedures [1] Group 2: Raw Material Approval - The company's magnesium sulfate raw material has been approved by the National Medical Products Administration for use in its registered formulations, indicating a solid foundation for its product offerings in the market [1]

Core Viewpoint - The company has received production registration approvals from the National Medical Products Administration of China for two pharmaceutical products, enhancing its portfolio in the ophthalmic and gastrointestinal preparation sectors [1] Group 1: Product Approvals - The company has obtained a production registration approval for Levofloxacin Eye Drops (0.488% concentration, 5ml: 24.4mg), classified as a Class 4 chemical drug, which is considered to have passed the consistency evaluation [1] - Levofloxacin Eye Drops are primarily used for treating various eye conditions, including blepharitis, meibomian gland inflammation, dacryocystitis, conjunctivitis, meibomian gland inflammation, keratitis, and for sterile chemotherapy during ophthalmic surgeries [1] - The approval enriches the company's range of ophthalmic formulations [1] Group 2: Additional Product Approvals - The company has also received approval for Compound Magnesium Sulfate Granules (10mg per bag), classified as a Class 3 chemical drug, which is also considered to have passed the consistency evaluation [1] - Compound Magnesium Sulfate Granules are mainly used for bowel cleansing prior to colonoscopy and X-ray examinations, and can also be utilized for bowel preparation before surgical procedures [1] - The company's magnesium sulfate active pharmaceutical ingredient has been approved for use in marketed formulations as of December 4, 2025 [1]

Core Viewpoint - The company has received production registration approvals from the National Medical Products Administration of China for two pharmaceutical products, enhancing its portfolio in the ophthalmic and gastrointestinal preparation sectors [1] Group 1: Product Approvals - The company obtained a production registration for Levofloxacin Eye Drops (0.488% (5ml: 24.4mg)), classified as a Class 4 chemical drug, which is considered to have passed the consistency evaluation [1] - Levofloxacin Eye Drops are primarily used for treating various eye conditions, including blepharitis, meibomian gland inflammation, dacryocystitis, conjunctivitis, meibomian gland inflammation, keratitis, and for sterile chemotherapy during ophthalmic surgeries [1] Group 2: Additional Product Development - The company also received approval for Compound Magnesium Sulfate Granules (10mg per bag), classified as a Class 3 chemical drug, which is also considered to have passed the consistency evaluation [1] - Compound Magnesium Sulfate Granules are mainly used for bowel cleansing prior to colonoscopy and X-ray examinations, as well as for bowel preparation before surgical procedures [1] - The company’s magnesium sulfate raw material has been approved for use in its registered formulations as of December 4, 2025 [1]

Core Viewpoint - The company has received production registration approvals from the National Medical Products Administration of China for two pharmaceutical products, enhancing its portfolio in the ophthalmic and gastrointestinal preparation sectors [1] Group 1: Product Approvals - The company has obtained a production registration for Levofloxacin Eye Drops (0.488% (5ml: 24.4mg)), classified as a Class 4 chemical drug, which is considered to have passed the consistency evaluation [1] - Levofloxacin Eye Drops are primarily used for treating various eye conditions, including blepharitis, meibomian gland inflammation, dacryocystitis, conjunctivitis, meibomian gland inflammation, keratitis, and for sterile chemotherapy during ophthalmic surgeries [1] - The approval increases the variety of ophthalmic formulations offered by the company [1] Group 2: Additional Product Approvals - The company has also received approval for Compound Magnesium Sulfate Granules (10mg per bag), classified as a Class 3 chemical drug, which is also considered to have passed the consistency evaluation [1] - Compound Magnesium Sulfate Granules are mainly used for bowel cleansing prior to colonoscopy and X-ray examinations, and can also be used for bowel preparation before surgical procedures [1] - The company’s magnesium sulfate active pharmaceutical ingredient has been registered with the National Medical Products Administration for use in marketed formulations [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不會就因本公告全部或任何部份內容而產生 或因倚賴該等內容而引致之任何損失承擔任何責任。 承董事局命 執行董事兼公司秘書 周興揚 香港，二零二五年十二月九日 於本公告日期，董事局成員包括執行董事曲繼廣先生、蘇學軍先生、孟國先生、周興揚先生及 曲婉蓉女士，非執行董事劉文軍先生，以及獨立非執行董事王亦兵先生、周國偉先生及姜廣策 先生。 - 2 - 自願公告 產品開發的最新進展 石四藥集團有限公司（「本公司」，連同其附屬公司，「本集團」）董事局（「董事局」）欣然公告， 本集團已取得中國國家藥品監督管理局（「國家藥監局」）有關左氧氟沙星滴眼液（0.488%（5ml： 24.4mg））的藥品生產註冊批件，屬於化學藥品第4類，視同通過一致性評價。左氧氟沙星滴眼 液主要用於治療眼瞼炎、瞼腺炎、淚囊炎、結膜炎、瞼板腺炎、角膜炎以及用於眼科圍手術期 的無菌化療法。本次獲批使本集團眼用製劑的品種日漸豐富。 董事局亦欣然公告，本集團已取得國家藥監局有關複方匹可硫酸鈉顆粒（每袋含匹可硫酸鈉 10mg），屬於化學藥 ...

Core Insights - The article discusses how Shijiazhuang, an old industrial city in Hebei Province, is transforming its economy by focusing on high-quality industrial development and creating five major industrial clusters worth over 100 billion yuan each [1][3]. Industrial Development - Shijiazhuang is revitalizing its economy by optimizing traditional industries, strengthening emerging sectors, and planning for future industries, with a focus on biomedicine, new-generation electronic information, advanced equipment manufacturing, modern food, and modern commercial logistics [1][3]. - The city has established a systematic approach to promote the five major industrial clusters, emphasizing policy guidance, technological innovation, and project construction [3][4]. Electronic Information Industry - The Luquan Economic Development Zone in Shijiazhuang has become a hub for the electronic information industry, hosting major companies and research institutes, and forming six advantageous industrial chains in semiconductor chips, modern communication, and more [2][4]. - The electronic information sector has seen significant growth, with revenue projected to increase from 771.7 billion yuan in 2021 to 1,381.7 billion yuan by 2024, reflecting an annual growth rate of 12.1% [5]. Biomedicine Sector - Shijiazhuang is recognized as a "Pharmaceutical Capital," with major companies like Shijiazhuang Pharmaceutical Group leading the industry. However, challenges remain in core technology and high-end talent acquisition [2][5]. - The biomedicine industry is expected to grow from 771 billion yuan in 2021 to 1,257.2 billion yuan by 2024, with an annual growth rate of 10.8% [5]. Innovation and R&D - The city has invested heavily in R&D, with a budget of 211.6 billion yuan for 2024, aiming to enhance technological innovation and industry integration [6][8]. - Shijiazhuang has established numerous partnerships with universities and research institutions to foster innovation, resulting in over 400 cooperation agreements and the establishment of multiple innovation platforms [7][8]. Talent Development - The city has implemented a talent strategy that includes various incentives and support measures, attracting over 10,000 young talents in 2024 alone [12][15]. - Shijiazhuang has created a favorable environment for talent retention, including housing support and financial incentives, contributing to its recognition as a top city for talent attraction [13][15]. Business Environment - Shijiazhuang is focused on creating a market-oriented, law-based, and international business environment, streamlining administrative processes and enhancing service efficiency for enterprises [9][10]. - The city has introduced measures to protect intellectual property rights, which are crucial for fostering innovation and ensuring fair competition [11].

石四药集团(02005)发布公告，集团的非奈利酮已获中国国家药品监督管理局批准登记成为在上市制剂 使用的原料药，是国内企业第二家获批。 非奈利酮主要用于与2型糖尿病相关的慢性肾脏病成人患者，可降低肾小球滤过率估计值(eGFR)持续下 降、终末期肾病、心血管死亡及因心力衰竭住院的风险。 ...

本文源自：财华网 【财华社讯】石四药集团(02005.HK)公布，集团的非奈利酮已获中国国家药品监督管理局批准登记成为 在上市制剂使用的原料药，是国內企业第二家获批。非奈利酮主要用于与2型糖尿病相关的慢性肾脏病 成人患者，可降低肾小球滤过率估计值(eGFR)持续下降、终末期肾病、心血管死亡及因心力衰竭住院 的风险。 ...

非奈利酮主要用于与2型糖尿病相关的慢性肾脏病成人患者，可降低肾小球滤过率估计值(eGFR) 持续下 降、终末期肾病、心血管死亡及因心力衰竭住院的风险。 智通财经APP讯，石四药集团(02005)发布公告，集团的非奈利酮已获中国国家药品监督管理局批准登记 成为在上市制剂使用的原料药，是国内企业第二家获批。 ...

格隆汇12月5日丨石四药集团(02005.HK)发布公告，集团的非奈利酮已获中国国家药品监督管理局批准 登记成为在上市制剂使用的原料药，是国内企业第二家获批。非奈利酮主要用于与2型糖尿病相关的慢 性肾脏病成人患者，可降低肾小球滤过率估计值(eGFR)持续下降、终末期肾病、心血管死亡及因心力 衰竭住院的风险。 ...